The results of a phase 1 trial of a messenger RNA vaccine, mRNA-1273, to prevent infection with SARS-CoV-2 has been recently reported; those interim results covered a period of 57 days after the first vaccination. In this article recently published in the New England Journal of Medicine, the authors further describe immunogenicity data 119 days after the first vaccination (90 days after the second vaccination) in 34 healthy adult participants in the same trial who received two injections of vaccine at a dose of 100 μg. The injections were received 28 days apart. The results of the study show that, despite a slight expected decline in titres of binding and neutralising antibodies, mRNA-1273 has the potential to provide durable humoral immunity.
DOI: 10.1056/NEJMc2032195